Median Study for Biochemical Serum Markers in First Trimester of Pregnancy
Launched by PERKINELMER, WALLAC OY · Jul 2, 2013
Trial Information
Current as of September 03, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • written informed consent
- • maternal age 18 - 45 years
- • gestational age 10 -13 (+6 days)verified by ultrasound
- Exclusion Criteria:
- • mental retardation or other mental disorders that impose doubts regarding the true subject's willingness to participate in the study
- • lack of needed demographic data
About Perkinelmer, Wallac Oy
PerkinElmer, Wallac Oy, a subsidiary of PerkinElmer Inc., is a leading global provider of innovative diagnostics and life science solutions. Specializing in advanced technologies for research and clinical applications, Wallac Oy focuses on delivering high-quality instruments and reagents for the detection and analysis of biological samples. With a commitment to enhancing healthcare outcomes through scientific excellence, the company plays a pivotal role in the development of diagnostic tools that empower researchers and clinicians in their efforts to improve patient care and accelerate scientific discoveries.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Khon Kaen, , Thailand
Seremban, , Malaysia
Caloocan City, , Philippines
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials